Kostaras, Eleftherios
Kaserer, Teresa
Lazaro, Glorianne
Heuss, Sara Farrah
Hussain, Aasia
Casado, Pedro
Hayes, Angela
Yandim, Cihangir
Palaskas, Nicolaos
Yu, Yi
Schwartz, Brian
Raynaud, Florence
Chung, Yuen-Li
Cutillas, Pedro R.
Vivanco, Igor http://orcid.org/0000-0001-6347-9416
Funding for this research was provided by:
Cancer Research UK (A21773, CRC553X, A21773, A21773, C16420/A18066, A21773, C1060/A16464, A21773)
RMH neuro-oncology research fund
RCUK | Biotechnology and Biological Sciences Research Council (BB/M006174/1)
Barts and The London Charity
Article History
Received: 10 September 2019
Revised: 7 April 2020
Accepted: 24 April 2020
First Online: 22 May 2020
Ethics approval and consent to participate
: EBC1 cells were obtained from the Japanese Collection of Research Bioresources (JCRB) Cell Bank. AU-565, HCC1419, H1694, HT29, ZR-75-1, Hs 746T, BT-474 and MDA-MB-361 cells were purchased from ATCC. EFM-192A cells were purchased from DSMZ. HGC27 cells were purchased from Cell Lines Service. HCT116 and DLD-1 AKT1/2 DKO cells were kindly provided by Bert Vogelstein (Johns Hopkins University).
: The whole-exome sequencing data described in this manuscript has been deposited in the publicly accessible ArrayExpress database (accession E-MTAB-8066). All other datasets can be found as part of this manuscript.
: Y.Y.: An employee of Arqule, Inc., who holds patents on miransertib and ARQ 751 and is undertaking the clinical development of these compounds. B.S.: An employee of Arqule, Inc., who holds patents on miransertib and ARQ 751 and is undertaking the clinical development of these compounds. All other authors declare no competing interests.
: E.K., G.L., S.F.H. and I.V. were supported by a CRUK programme foundation award (A21773). T.K. is funded by Cancer Research UK Accelerator Award (CRC553X). A.H. was supported through the RMH neuro-oncology research fund. P.C. and P.R.C. were supported by grants from Barts and The London Charity (297/2249), CRUK (C16420/A18066) and BBSRC (BB/M006174/1). Y.-L.C. was supported through grants from CRUK Cancer Imaging Centre (C1060/A16464) in association with the MRC and Department of Health (England), and funding from NHS to the NIHR Biomedical Research Centre. HCT116 and DLD-1 AKT1/2 DKO cells were kindly provided by Bert Vogelstein (Johns Hopkins University).